HTG Molecular Diagnostics, Inc. ("HTG") is a provider of instruments, reagents, and services for molecular profiling applications. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of multiplexed profiling panels that leverage HTGâs proprietary nuclease protection chemistry. In 2014, the company launched the HTG EdgeSeq system that combines the power of HTG EdgeSeq chemistry and automation with next-generation sequencing (NGS) technology. In 2016, the VERI/O Laboratory Services were introduced to support biopharma clients in research and companion diagnostic development using retrospective samples. Most recently, in 2017, HTG introduced its new DNA mutations chemistry available exclusively in the VERI/O Laboratory Services. Source
No articles found.
Quadrant Biosciences is an epigenetic diagnostics company with a focus on the earl...
Quadrant Biosciences is an epigenetic diagnosti...
PhaseBio is a clinical-stage biopharmaceutical company focused on the development ...
PhaseBio is a clinical-stage biopharmaceutical ...
Grifols is a global healthcare company founded in Barcelona in 1909 committed to i...
Grifols is a global healthcare company founded ...
Intrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with B...
Intrexon Corporation (NASDAQ: XON) is Powering ...
IMAC Holdings, Inc. owns or manages IMAC Regeneration Centers, which combine life ...
IMAC Holdings, Inc. owns or manages IMAC Regene...
We are a gene therapy company dedicated to developing and commercializing novel tr...
We are a gene therapy company dedicated to deve...
Harvard Bioscience is a global developer, manufacturer and marketer of a broad ran...
Harvard Bioscience is a global developer, manuf...
Join the National Investor Network and get the latest information with your interests in mind.